The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

Roche RHHBY announced today that the FDA has approved a label expansion of ophthalmology drug Susvimo (ranibizumab injection). The regulatory body approved the drug Susvimo for the treatment of ...

Liquidia Corporation (NASDAQ:LQDA) said on Friday that the U.S. FDA has approved Yutrepia inhalation powder, a prostacyclin ...

Triangle firm slaps feds with lawsuit over delayed product launch Morrisville firm stunned by FDA setback, vows 'quick action ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved ...

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...

The US Food and Drug Administration's (FDA) March 4, 2022, approval of nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable (tumors ≥4 cm or node ...

The Food and Drug administration has approved the U.S.'s first at-home alternative to the Pap smear, a procedure generations of women have dreaded and often found painful. The new device by Teal ...

May 9 (UPI) --The U.S. Food and Drug Administration on Friday approved three new natural food color additives, part of Department of Health and Human Services Secretary Robert F. Kennedy Jr.'s ...